Photobiomodulation therapy and the glymphatic system: promising applications for augmenting the brain lymphatic drainage system

F Salehpour, M Khademi, DE Bragin… - International journal of …, 2022 - mdpi.com
The glymphatic system is a glial-dependent waste clearance pathway in the central nervous
system, devoted to drain away waste metabolic products and soluble proteins such as …

The beneficial role of photobiomodulation in neurodegenerative diseases

A Abijo, CY Lee, CY Huang, PC Ho, KJ Tsai - Biomedicines, 2023 - mdpi.com
Photobiomodulation (PBM), also known as Low-level Laser Therapy (LLLT), involves the
use of light from a laser or light-emitting diode (LED) in the treatment of various disorders …

Promoted CD4+ T cell-derived IFN-γ/IL-10 by photobiomodulation therapy modulates neurogenesis to ameliorate cognitive deficits in APP/PS1 and 3xTg-AD mice

X Wu, Q Shen, H Chang, J Li, D Xing - Journal of Neuroinflammation, 2022 - Springer
Background The immune system has been implicated in synaptic plasticity, inflammation,
and the progression of Alzheimer's disease (AD). However, there were few studies on …

Pregabalin mitigates microglial activation and neuronal injury by inhibiting HMGB1 signaling pathway in radiation-induced brain injury

Z Zhang, J Jiang, Y He, J Cai, J Xie, M Wu… - Journal of …, 2022 - Springer
Background Radiation-induced brain injury (RIBI) is the most serious complication of
radiotherapy in patients with head and neck tumors, which seriously affects the quality of life …

Phosphodiesterase inhibitors for Alzheimer's disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale

O Sanders, L Rajagopal - Journal of Alzheimer's Disease …, 2020 - content.iospress.com
Background: Preclinical studies, clinical trials, and reviews suggest increasing 3', 5'-cyclic
adenosine monophosphate (cAMP) and 3', 5'-cyclic guanosine monophosphate (cGMP) with …

Phototherapy of Alzheimer's disease: photostimulation of brain lymphatics during sleep: a systematic review

O Semyachkina-Glushkovskaya, T Penzel… - International Journal of …, 2023 - mdpi.com
The global number of people with Alzheimer's disease (AD) doubles every 5 years. It has
been established that unless an effective treatment for AD is found, the incidence of AD will …

[HTML][HTML] Ginsenoside Rg1 alleviates Aβ deposition by inhibiting NADPH oxidase 2 activation in APP/PS1 mice

H Zhang, Y Su, Z Sun, M Chen, Y Han, Y Li… - Journal of ginseng …, 2021 - Elsevier
Abstract Background Ginsenoside Rg1 (Rg1), an active ingredient in ginseng, may be a
potential agent for the treatment of Alzheimer's disease (AD). However, the protective effect …

Sirtuins as potential therapeutic targets for mitigating neuroinflammation associated with Alzheimer's disease

KKM Fernando, YS Wijayasinghe - Frontiers in Cellular Neuroscience, 2021 - frontiersin.org
Alzheimer's disease (AD) is the most common neurodegenerative disorder, which is
associated with memory deficit and global cognitive decline. Age is the greatest risk factor …

Antiallergic drug desloratadine as a selective antagonist of 5HT2A receptor ameliorates pathology of Alzheimer's disease model mice by improving microglial …

J Lu, C Zhang, J Lv, X Zhu, X Jiang, W Lu, Y Lu… - Aging …, 2021 - Wiley Online Library
Alzheimer's disease (AD) is a progressively neurodegenerative disease characterized by
cognitive deficits and alteration of personality and behavior. As yet, there is no efficient …

Alzheimer's disease-related epigenetic changes: novel therapeutic targets

A Paniri, MM Hosseini, H Akhavan-Niaki - Molecular Neurobiology, 2024 - Springer
Aging is a significant risk factor for Alzheimer's disease (AD), although the precise
mechanism and molecular basis of AD are not yet fully understood. Epigenetic mechanisms …